Autoimmune Neuromuscular Disorders and Management Strategies

Autoimmune neuromuscular disorders encompass a spectrum of conditions in which the immune system erroneously targets components of the peripheral motor system, leading to muscle weakness, fatigability and, in severe cases, respiratory compromise. Classical examples include myasthenia gravis, characterised by autoantibodies to the acetylcholine receptor or related postsynaptic proteins, and Lambert–Eaton myasthenic syndrome, in which antibodies disrupt presynaptic calcium channels. Other entities such as immune-mediated neuropathies and inflammatory myopathies further illustrate the diverse mechanisms by which autoreactive B cells, T cells and complement activation impair neuromuscular transmission or muscle integrity. Management strategies have evolved from broad immunosuppression and symptomatic agents, such as cholinesterase inhibitors, to thymectomy in selected myasthenia gravis patients and advanced extracorporeal techniques including plasma exchange and immunoadsorption. The past decade has seen the emergence of targeted biologic therapies—monoclonal antibodies against B-cell markers, complement inhibitors and receptor-specific antagonists—that offer greater precision with improved safety profiles. Personalised treatment algorithms now draw upon autoantibody profiling, disease subtype and severity to optimise outcomes, reduce relapse rates and preserve quality of life across global healthcare settings.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Autoimmune Neuromuscular Disorders and Management Strategies publication trend

The graph below shows the total number of articles in autoimmune neuromuscular disorders and management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Autoantibody: A self-reactive immunoglobulin that targets components of the neuromuscular interface, disrupting normal function.

Neuromuscular junction: The specialised synapse where motor neuron terminals release acetylcholine to trigger skeletal muscle contraction.

Immunoadsorption: A blood-purification technique that selectively removes pathogenic antibodies from the circulation.

Complement-mediated damage: Tissue injury resulting from activation of the complement cascade by antigen–antibody complexes at the neuromuscular junction.

Biologic agents: Therapeutic proteins, often monoclonal antibodies, designed to modulate specific immune pathways involved in autoimmunity.

References

1. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology (2020).
2. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Frontiers in Immunology (2020).
3. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Frontiers in Immunology (2019).